British Journal of Cancer最新文献_第10页

Integrated proteomics and scRNA-seq analyses of ovarian cancer reveal molecular subtype-associated cell landscapes and immunotherapy targets 卵巢癌蛋白质组学和 scRNA-seq 整合分析揭示了分子亚型相关细胞景观和免疫疗法靶点。

IF 6.4 1区医学

British Journal of Cancer Pub Date : 2024-11-15 DOI: 10.1038/s41416-024-02894-2

Rong Tan, Ming Wen, Wenqing Yang, Dongdong Zhan, Nairen Zheng, Mingwei Liu, Fang Zhu, Xiaodan Chen, Meng Wang, Siyu Yang, Bin Xie, Qiongqiong He, Kai Yuan, Lunquan Sun, Yi Wang, Jun Qin, Yu Zhang

{"title":"Integrated proteomics and scRNA-seq analyses of ovarian cancer reveal molecular subtype-associated cell landscapes and immunotherapy targets","authors":"Rong Tan, Ming Wen, Wenqing Yang, Dongdong Zhan, Nairen Zheng, Mingwei Liu, Fang Zhu, Xiaodan Chen, Meng Wang, Siyu Yang, Bin Xie, Qiongqiong He, Kai Yuan, Lunquan Sun, Yi Wang, Jun Qin, Yu Zhang","doi":"10.1038/s41416-024-02894-2","DOIUrl":"10.1038/s41416-024-02894-2","url":null,"abstract":"Epithelial ovarian cancer (EOC) represents the most lethal gynaecological malignancy, yet understanding the connections between its molecular subtypes and their therapeutic implications remains incomplete. We conducted mass spectrometry-based proteomics analyses of 154 EOC tumour samples and 29 normal fallopian tubes, and single-cell RNA sequencing (scRNA-seq) analyses of an additional eight EOC tumours to classify proteomic subtypes and assess their cellular ecosystems and clinical significance. The efficacy of identified therapeutic targets was evaluated in patient-derived xenograft (PDX) and orthotopic mouse models. We identified four proteomic subtypes with distinct clinical relevance: malignant proliferative (C1), immune infiltrating (C2), Fallopian-like (C3) and differentiated (C4) subtypes. C2 subtype was characterized by lymphocyte infiltration, notably an increased presence of GZMK CD8+ T cells and phagocytosis-like MRC+ macrophages. Additionally, we identified CD40 as a specific prognostic factor for C2 subtype. The interaction between CD40+ phagocytosis-like macrophages and CD40RL+ IL17R CD4+ T cells was correlated with a favourable prognosis. Finally, we established a druggable landscape for non-immune EOC patients and verified a TYMP inhibitor as a promising therapeutic strategy. Our study refines the current immune subtype for EOC, highlighting CD40 agonists as promising therapies for C2 subtype patients and targeting TYMP for non-immune patients.","PeriodicalId":9243,"journal":{"name":"British Journal of Cancer","volume":"132 1","pages":"111-125"},"PeriodicalIF":6.4,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41416-024-02894-2.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142638293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Phenotypical differences of neutrophils patrolling tumour-draining lymph nodes in head and neck cancer 头颈癌肿瘤引流淋巴结中性粒细胞的表型差异。

IF 6.4 1区医学

British Journal of Cancer Pub Date : 2024-11-14 DOI: 10.1038/s41416-024-02891-5

Sandra Ekstedt, Krzysztof Piersiala, Aeneas Kolev, Pedro Farrajota Neves da Silva, Gregori Margolin, Susanna Kumlien Georén, Lars-Olaf Cardell

{"title":"Phenotypical differences of neutrophils patrolling tumour-draining lymph nodes in head and neck cancer","authors":"Sandra Ekstedt, Krzysztof Piersiala, Aeneas Kolev, Pedro Farrajota Neves da Silva, Gregori Margolin, Susanna Kumlien Georén, Lars-Olaf Cardell","doi":"10.1038/s41416-024-02891-5","DOIUrl":"10.1038/s41416-024-02891-5","url":null,"abstract":"The complexity and heterogeneity of neutrophils are recognized, especially their roles in modulating inflammation and cancer immune responses. The detailed functions of neutrophils in human tumour-draining lymph nodes (TDLNs), specifically in the context of head and neck cancer, remain inadequately characterized. This study aims to delineate the phenotypic diversity of neutrophils in TDLNs, non-tumour-draining lymph nodes (nTDLNs) from patients with oral squamous cell carcinoma (OSCC), and to evaluate their correlation with clinical outcomes. A flow cytometry-based investigation. Neutrophils manifest a tissue-specific heterogeneity with significant phenotypic differences between compartments. A substantial fraction of neutrophils displayed an activated CD16highCD62Ldim profile in TDLNs, more prominent in patients with advanced T stages, implicating their involvement in the disease’s progression. Notably, the presence of this activated neutrophil phenotype in TDLNs was strongly associated with poorer patient prognosis. The study confirms the heterogeneity of neutrophils in human TDLNs, aligning with findings from animal models but extending them to show clinical relevance in human disease. The correlation of neutrophil phenotypes with cancer progression and prognosis emphasizes the importance of these cells in the tumour-microenvironment. The data suggests a future possibility to develop targeted therapies that modulate the neutrophilic response in OSCC.","PeriodicalId":9243,"journal":{"name":"British Journal of Cancer","volume":"131 12","pages":"1893-1900"},"PeriodicalIF":6.4,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41416-024-02891-5.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142615132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The abscopal effects of sonodynamic therapy in cancer 声动力疗法对癌症的缺席效应。

IF 6.4 1区医学

British Journal of Cancer Pub Date : 2024-11-13 DOI: 10.1038/s41416-024-02898-y

Victoria G. Collins, Dana Hutton, Kismet Hossain-Ibrahim, James Joseph, Sourav Banerjee

{"title":"The abscopal effects of sonodynamic therapy in cancer","authors":"Victoria G. Collins, Dana Hutton, Kismet Hossain-Ibrahim, James Joseph, Sourav Banerjee","doi":"10.1038/s41416-024-02898-y","DOIUrl":"10.1038/s41416-024-02898-y","url":null,"abstract":"The abscopal effect is a phenomenon wherein localised therapy on the primary tumour leads to regression of distal metastatic growths. Interestingly, various pre-clinical studies utilising sonodynamic therapy (SDT) have reported significant abscopal effects, however, the mechanism remains largely enigmatic. SDT is an emerging non-invasive cancer treatment that uses focussed ultrasound (FUS) and a sonosensitiser to induce tumour cell death. To expand our understanding of abscopal effects of SDT, we have summarised the preclinical studies that have found SDT-induced abscopal responses across various cancer models, using diverse combination strategies with nanomaterials, microbubbles, chemotherapy, and immune checkpoint inhibitors. Additionally, we shed light on the molecular and immunological mechanisms underpinning SDT-induced primary and metastatic tumour cell death, as well as the role and efficacy of different sonosensitisers. Notably, the observed abscopal effects underscore the need for continued investigation into the SDT-induced ‘vaccine-effect’ as a potential strategy for enhancing systemic anti-tumour immunity and combating metastatic disease. The results of the first SDT human clinical trials are much awaited and are hoped to enable the further evaluation of the safety and efficacy of SDT, paving the way for future studies specifically designed to explore the potential of translating SDT-induced abscopal effects into clinical reality.","PeriodicalId":9243,"journal":{"name":"British Journal of Cancer","volume":"132 5","pages":"409-420"},"PeriodicalIF":6.4,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41416-024-02898-y.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142615133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparing cancer stage at diagnosis between migrants and non-migrants: a meta-analysis 比较移民和非移民确诊时的癌症分期：一项荟萃分析。

IF 6.4 1区医学

British Journal of Cancer Pub Date : 2024-11-12 DOI: 10.1038/s41416-024-02896-0

Adam Harvey-Sullivan, Sana Ali, Parveen Dhesi, Joseph Hart, Helena Painter, Fiona M. Walter, Garth Funston, Dominik Zenner

{"title":"Comparing cancer stage at diagnosis between migrants and non-migrants: a meta-analysis","authors":"Adam Harvey-Sullivan, Sana Ali, Parveen Dhesi, Joseph Hart, Helena Painter, Fiona M. Walter, Garth Funston, Dominik Zenner","doi":"10.1038/s41416-024-02896-0","DOIUrl":"10.1038/s41416-024-02896-0","url":null,"abstract":"Migrants face barriers accessing healthcare, risking delays in cancer diagnosis. Diagnostic delays result in later stage diagnosis which is associated with poorer cancer survival. This review aims to compare the differences in cancer stage at diagnosis between migrants and non-migrants. We conducted a systematic review and meta-analysis of three databases from 2000 to 2023 for studies conducted in OECD countries that compared stage at diagnosis between migrants and non-migrants. Meta-analysis compared odds ratios (OR) for early (stage I and II) stage at diagnosis. The Risk of Bias in Non-randomised Studies of Exposure tool was used to assess study quality. 41 of the 11,549 studies identified were included; 34 studies had suitable data for meta-analysis. Overall, migrants were significantly less likely to be diagnosed with early stage cancer compared with non-migrants (OR 0.84; 95% CI 0.78–0.91). This difference was maintained across cancer types, although only statistically significant for breast (OR 0.78; 95% CI 0.70–0.87) and prostate cancer (OR 0.92; 95% CI 0.85–0.99). Published studies indicate that migrants are less likely to be diagnosed with early stage cancer. Variation by cancer type, study location and region of origin highlights the need for further research to understand these differences.","PeriodicalId":9243,"journal":{"name":"British Journal of Cancer","volume":"132 2","pages":"158-167"},"PeriodicalIF":6.4,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41416-024-02896-0.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142615130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction: Height and breast cancer risk in premenopausal Korean women aged under 40 years of age 更正：40 岁以下绝经前韩国女性的身高与乳腺癌风险。

IF 6.4 1区医学

British Journal of Cancer Pub Date : 2024-11-11 DOI: 10.1038/s41416-024-02886-2

Thi Xuan Mai Tran, Yoosoo Chang, Hye Rin Choi, Ria Kwon, Ga-Young Lim, Yoosun Cho, Seungho Ryu, Boyoung Park

引用次数: 0

VEGF-C propagates ‘onward’ colorectal cancer metastasis from liver to lung VEGF-C 促使大肠癌从肝脏向肺部 "继续 "转移。

IF 6.4 1区医学

British Journal of Cancer Pub Date : 2024-11-09 DOI: 10.1038/s41416-024-02892-4

Susanna Poghosyan, Nicola Frenkel, Lotte van den Bent, Danielle Raats, Tessa Spaapen, Jamila Laoukili, Inne Borel Rinkes, Onno Kranenburg, Jeroen Hagendoorn

{"title":"VEGF-C propagates ‘onward’ colorectal cancer metastasis from liver to lung","authors":"Susanna Poghosyan, Nicola Frenkel, Lotte van den Bent, Danielle Raats, Tessa Spaapen, Jamila Laoukili, Inne Borel Rinkes, Onno Kranenburg, Jeroen Hagendoorn","doi":"10.1038/s41416-024-02892-4","DOIUrl":"10.1038/s41416-024-02892-4","url":null,"abstract":"The formation of lung metastasis as part of the progression of colon cancer is a poorly understood process. Theoretically, liver metastases could seed lung metastases. To assess the contribution of the liver lymphatic vasculature to metastatic spread to the lungs, we generated murine liver-metastasis-derived organoids overexpressing vascular endothelial growth factor (VEGF)-C. The organoids were reimplanted into the mouse liver for tumour generation and onward metastasis. Liver metastases from patients with concomitant lung metastases showed higher expression of VEGF-C, lymphatic vessel hyperplasia, and tumour cell invasion into lymphatic vessels when compared to those without lung metastases. Reimplantation of VEGF-C overexpressing organoids into the mouse liver showed that VEGF-C caused peritumoral lymphatic vessel hyperplasia, lymphatic tumour cell invasion, and lung metastasis formation. This change in metastatic organotropism was accompanied by reduced expression of WNT-driven adult stem cell markers, and increased expression of fetal stem cell markers and NOTCH pathway genes. Further NOTCH pathway inhibition with γ-secretase inhibitor (DAPT) in vivo results in a slight reduction in lung metastases and a decrease in lymphatic hyperplasia and invasion in VEGF-C-overexpressing tumours. Collectively, these data indicate that VEGF-C can drive onward metastasis from the liver to the lung and suggest that targeting VEGF-C/NOTCH pathways may impair the progression of colorectal cancer.","PeriodicalId":9243,"journal":{"name":"British Journal of Cancer","volume":"132 1","pages":"69-80"},"PeriodicalIF":6.4,"publicationDate":"2024-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142615134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cardiotoxicity following thoracic radiotherapy for lung cancer 肺癌胸腔放疗后的心脏毒性。

IF 6.4 1区医学

British Journal of Cancer Pub Date : 2024-11-06 DOI: 10.1038/s41416-024-02888-0

Gerard M. Walls, Carmen Bergom, Joshua D. Mitchell, Stacey L. Rentschler, Geoffrey D. Hugo, Pamela P. Samson, Clifford G. Robinson

{"title":"Cardiotoxicity following thoracic radiotherapy for lung cancer","authors":"Gerard M. Walls, Carmen Bergom, Joshua D. Mitchell, Stacey L. Rentschler, Geoffrey D. Hugo, Pamela P. Samson, Clifford G. Robinson","doi":"10.1038/s41416-024-02888-0","DOIUrl":"10.1038/s41416-024-02888-0","url":null,"abstract":"Radiotherapy is the standard of care treatment for unresectable NSCLC, combined with concurrent chemotherapy and adjuvant immunotherapy. Despite technological advances in radiotherapy planning and delivery, the risk of damage to surrounding thoracic tissues remains high. Cardiac problems, including arrhythmia, heart failure and ischaemic events, occur in 20% of patients with lung cancer who undergo radiotherapy. As survival rates improve incrementally for this cohort, minimising the cardiovascular morbidity of RT is increasingly important. Problematically, the reporting of cardiac endpoints has been poor in thoracic radiotherapy clinical trials, and retrospective studies have been limited by the lack of standardisation of nomenclature and endpoints. How baseline cardiovascular profile and cardiac substructure radiation dose distribution impact the risk of cardiotoxicity is incompletely understood. As Thoracic Oncology departments seek to expand the indications for radiotherapy, and as the patient cohort becomes older and more comorbid, there is a pressing need for cardiotoxicity to be comprehensively characterised with sophisticated oncology, physics and cardio-oncology evaluations. This review synthesises the evidence base for cardiotoxicity in conventional radiotherapy, focusing on lung cancer, including current data, unmet clinical needs, and future scientific directions.","PeriodicalId":9243,"journal":{"name":"British Journal of Cancer","volume":"132 4","pages":"311-325"},"PeriodicalIF":6.4,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41416-024-02888-0.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142590072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Perioperative safety of risk-reducing mastectomy 降低风险的乳房切除术的围手术期安全性。

IF 6.4 1区医学

British Journal of Cancer Pub Date : 2024-11-05 DOI: 10.1038/s41416-024-02897-z

Samuel Knoedler, Fortunay Diatta, Felix Kasparbauer, Leonard Knoedler, Bong-Sung Kim, Bohdan Pomahac, Martin Kauke-Navarro

引用次数: 0

Low-dose arsenic trioxide inhibits pancreatic stellate cell activation via LOXL3 expression to enhance immunotherapy in pancreatic cancer 小剂量三氧化二砷通过 LOXL3 的表达抑制胰腺星状细胞的活化，从而增强胰腺癌的免疫疗法。

IF 6.4 1区医学

British Journal of Cancer Pub Date : 2024-11-05 DOI: 10.1038/s41416-024-02880-8

Yue Zhao, Yunlong Li, Jinmao Zou, Tairan Guo, Ziyi Zhong, Yaqing Li, Shaojie Chen, Jiajia Li, Kaihong Huang, Guoda Lian, Yuzhou Huang

{"title":"Low-dose arsenic trioxide inhibits pancreatic stellate cell activation via LOXL3 expression to enhance immunotherapy in pancreatic cancer","authors":"Yue Zhao, Yunlong Li, Jinmao Zou, Tairan Guo, Ziyi Zhong, Yaqing Li, Shaojie Chen, Jiajia Li, Kaihong Huang, Guoda Lian, Yuzhou Huang","doi":"10.1038/s41416-024-02880-8","DOIUrl":"10.1038/s41416-024-02880-8","url":null,"abstract":"Pancreatic cancer (PC) is characterized by abnormally fibrotic mesenchyme, which notably influences on the effectiveness of immunotherapy. Low-dose arsenic trioxide (ATO, 1.0 μM) can inhibit the activation of pancreatic stellate cells (PSCs) and affect fibrosis, which is a potential strategy for enhancing the sensitivity to immunotherapy. Extracellular matrix (ECM) models were employed to assess the regulatory effects of ATO on ECM and peripheral blood mononuclear cells. Orthotopic C57BL/6J models were utilized to evaluate the influence of ATO on CD8+T cell infiltration and immunotherapy in PC. Additionally, nanomaterials loaded with ATO designed to specifically target PSCs (scAbFAP-α-HMSNs-PAA-ATO) were produced to enhance targeting effects of ATO. Low-dose ATO (1.0 μM) suppressed PSCs activation, exhibiting potential for synergistic immunotherapy. Under low-dose ATO intervention, ECM underwent remodeling, leading to increases in CD8+T cell infiltration, thereby enhancing anti-PD-L1 therapy effect. We further demonstrated that low-dose ATO remodeled ECM by regulating the expression of LOXL3 in PSCs. scAbFAP-α-HMSNs-PAA-ATO exhibited improved targeting capabilities, and enhanced capacity to inhibit fibrosis and sensitize immunotherapy. Our research reveals that low-dose ATO, by regulating LOXL3, remodels the ECM and enhances CD8+T cell infiltration, thus sensitizing the efficacy of immunotherapy, which provides a novel strategy for comprehensive treatment to PC.","PeriodicalId":9243,"journal":{"name":"British Journal of Cancer","volume":"131 12","pages":"1928-1941"},"PeriodicalIF":6.4,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142582140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-world evidence for pembrolizumab in non-small cell lung cancer: a nationwide cohort study pembrolizumab治疗非小细胞肺癌的现实证据：一项全国性队列研究。

IF 6.4 1区医学

British Journal of Cancer Pub Date : 2024-11-03 DOI: 10.1038/s41416-024-02895-1

Helga H. Hektoen, Kaitlyn M. Tsuruda, Lars Fjellbirkeland, Yngvar Nilssen, Odd Terje Brustugun, Bettina K. Andreassen

{"title":"Real-world evidence for pembrolizumab in non-small cell lung cancer: a nationwide cohort study","authors":"Helga H. Hektoen, Kaitlyn M. Tsuruda, Lars Fjellbirkeland, Yngvar Nilssen, Odd Terje Brustugun, Bettina K. Andreassen","doi":"10.1038/s41416-024-02895-1","DOIUrl":"10.1038/s41416-024-02895-1","url":null,"abstract":"Based on favourable results from clinical trials, immune checkpoint inhibitors (ICI) have become the standard first line (1 L) systemic anticancer treatment (SACT) for advanced stage non-small cell lung cancer (NSCLC) without targetable mutations. We evaluate whether these results are generalizable to everyday clinical practice and compare overall survival (OS) of patients treated with ICI to a historical cohort of patients treated with chemotherapy and results from clinical trials. Our study comprised all advanced NSCLC patients initiating SACT in 2012–21 in Norway. Clinical characteristics and treatment information was retrieved from Norwegian Health Registries. Survival for all 8416 advanced NSCLC patients treated with SACT increased concurrently with the gradual implementation of ICIs. Median OS of patients treated with 1 L pembrolizumab after 2017 was better (mono-/combination therapy: 13.8/12.8 months) than for patients treated with chemotherapy before 2017 (8.0 months). Although median OS for patients treated with pembrolizumab was lower in clinical practice than clinical trials (Keynote-024/189: 26.3/22.0 months), the survival benefit relative to chemotherapy was similar. Our nationwide study demonstrated a survival benefit over conventional chemotherapy of a similar magnitude as observed in clinical trials and confirms the effectiveness of pembrolizumab in routine clinical practice.","PeriodicalId":9243,"journal":{"name":"British Journal of Cancer","volume":"132 1","pages":"93-102"},"PeriodicalIF":6.4,"publicationDate":"2024-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41416-024-02895-1.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142567347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0